News Column

Ventripoint Announces New Vice-President of Sales and Marketing

May 30 2013 12:00AM

Marketwire

LogoTracker

SEATTLE, WASHINGTON -- (Marketwired) -- 05/30/13 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE: VPT)(OTCQX: VPTDF) announces that it has hired Mr. Jerry Gatewood as its Vice-President of Sales and Marketing.

Mr. Gatewood has over 18 years of introducing new medical products with extensive experience in sales and marketing of imaging equipment. He was Global Market Manager for ATL Ultrasound (now Philips Medical Systems), where he created and executed global marketing and market introduction plans, and Director of U.S. Marketing for SonoSite (now part of FujiFilm) where he managed the U.S. marketing team and identified and developed new markets. He was also Director for Global Sales for Merge CAD, where he established, negotiated and managed all aspects of original equipment manufacturer (OEM) partnerships, while securing national U.S. account agreements with major group purchasing organizations.

"It is with great pleasure that I welcome Jerry to the team" said Dr. George Adams, CEO of Ventripoint. "Jerry's 'been-there-done-that' wisdom will lead us as we prepare for expanding sales into the U.S. and the rest of the world."

"I am very excited at the opportunity to be a part of the Ventripoint team. This Company and its technology have a great potential to positively impact patient care and I am proud to be part of that movement" said Jerry Gatewood, VP of Sales and Marketing.

Mr. Amol Karnick will continue to be a consultant to the Company and focus on Business Development.

About Ventripoint Diagnostics Ltd.

Ventripoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes that VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children and adults and Pulmonary Arterial Hypertension are the first applications in a suite of applications for all major heart diseases including cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ tool and the Company is pursuing the US-FDA marketing clearance through the 510(k) process.

FORWARD-LOOKING STATEMENTS: This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the closing of the private placements including the Company's ability to obtain necessary approvals from the TSX Venture Exchange. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Ventripoint Diagnostics Ltd.
Dr. George Adams
CEO
(206) 910-9125
gadams@ventripoint.com





Source: Marketwire


Story Tools